Introduction

StemCells, Inc. reports positive interim safety data from spinal cord injury trial

StemCells, Inc. reports positive interim safety data from spinal cord injury trial

StemCells, Inc. has announced completion of the first planned interim safety review of the company’s Phase I/II spinal cord injury clinical trial, which indicated that the surgery, immunosuppression and the cell transplants have been well-tolerated. The trial, which is designed to evaluate the safety and preliminary efficacy of the their proprietary HuCNS-SC® cells, represents the first time that neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury.

Read more…